Westat is supporting an Ansun BioPharma study that is showing positive results for a treatment for Severe COVID-19. DAS181 is a multicenter, double-blinded, randomized-controlled study. Westat is supporting the study by recruiting and readying sites to participate in a COVID-19 clinical trial as quickly as possible.
Within a week of the contract award, our Clinical Trials team, led by Nancy Dianis, quickly contacted 30 possible sites. Just 1 week later, they had 11 sites on board. The Westat team—including Lauren Laimon, Michele Snyder, Tracy Wolbach, Melissa King, and Sylvia Resler—created clinical site agreements, site budgets, and regulatory documentation and handled contract issues in record time. Two sites are already ready to receive patients as soon as they receive approval from local institutional review boards.